2025-08-29 03:51:21
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Sandu Pharmaceuticals Ltd Q2 FY2024 consolidated PAT at Rs. 55.06 lakhs
Posted On : 2023-11-13 20:49:23( TIMEZONE : IST )
SANDU PHARMACEUTICALS LTD. has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 16.6941 crores during the period ended September 30, 2023 as compared to Rs. 17.6581 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 0.5506 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 0.1093 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 0.57 for the period ended September 30, 2023 as compared to Rs. 0.11 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 16.6941 crs | ₹17.6581 crs |  -5.46% |
| Net Profit | ₹0.5506 crs | ₹0.1093 crs |  403.75% |
| EPS | ₹0.57 | ₹0.11 | 418.18% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 16.6941 crores during the period ended September 30, 2023 as compared to Rs.16.9320 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.0.5506 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.0.5983 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.0.57 for the period ended September 30, 2023 as compared to Rs.0.64 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 16.6941 crs | ₹16.9320 crs | -1.41% |
| Net Profit | ₹0.5506 crs | ₹0.5983 crs | -7.97% |
| EPS | ₹0.57 | ₹0.64 | -10.94% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.34.3522 crores during the 6 Months period ended September 30, 2023 as compared to Rs.33.2464 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.0.6603 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.0.7674 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.0.68 for the 6 Months period ended September 30, 2023 as compared to Rs.0.84 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹34.3522 crs | ₹33.2464 crs | 3.33% |
| Net Profit | ₹0.6603 crs | ₹0.7674 crs | -13.96% |
| EPS | ₹0.68 | ₹0.84 | -19.05% |
Shares of SANDU PHARMACEUTICALS LTD. was last trading in BSE at Rs. 67.71 as compared to the previous close of Rs. 68.97. The total number of shares traded during the day was 2484 in over 29 trades.
The stock hit an intraday high of Rs. 69.70 and intraday low of 65.60. The net turnover during the day was Rs. 169038.00.
